MarketFriction

Jubilant Pharmova Ltd

NSE JUBLPHARMA · BSE 530019 · Pharmaceuticals
₹999.30 -2.87%
NSE close2026-10-01
52 week range786.05 - 1,184.80
Market cap₹16,698 Cr.
P/E43.0
Microcap 250 Price band 20% Delivery 51.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,6801,6771,7591,7321,7521,8221,9291,9011,9662,1222,2902,229
Expenses1,4381,4591,4871,4801,4631,5351,5841,6111,6251,8331,9511,981
Operating Profit242218271252289287345290341289339248
OPM %14%13%15%15%17%16%18%15%17%14%15%11%
Other Income1949-1514108-109124-191020
Interest667173716156534950565654
Depreciation97951019191919598105121117127
Profit before tax98101-545001441302061541909317686
Tax %37%34%15%4%29%23%27%34%37%40%32%35%
Net Profit6266-624821021011511021205611956
EPS in Rs3.924.19-3.6830.266.456.339.646.467.553.517.503.55
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5,7495,8617,5189,1115,9766,0996,1306,2826,7037,2348,2808,608
Expenses4,4934,5105,9957,3674,4284,6954,9805,5035,8026,0617,0207,390
Operating Profit1,2561,3521,5221,7441,5481,4031,1507799011,1731,2601,218
OPM %22%23%20%19%26%23%19%12%13%16%15%14%
Other Income41936-2492252638-9-76416715
Interest371341284220200184145188272240212217
Depreciation347291415371340349382554382369440470
Profit before tax5427388599041,2331,13363028170981614546
Tax %29%22%26%36%27%26%34%333%57%15%35%
Net Profit387575634577898836413-6573836398351
EPS in Rs24.6036.1440.3536.0656.3952.4725.98-3.834.8452.6925.0222.11
Dividend Payout %12%8%7%12%9%10%19%-130%102%9%20%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth4%6%10%16%
Compounded Profit Growth1%-13%47%-20%
Stock Price CAGR7%11%34%-3%
Return on Equity9%3%5%7%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161616161616161616161616
Reserves2,4382,9513,4204,0714,7935,5884,7265,3035,3835,4186,2397,077
Borrowings4,7934,4934,0453,4694,8404,8082,8303,1923,6773,6642,7313,615
Other Liabilities1,3721,2801,4171,9021,6701,8981,1921,3191,8532,2403,5984,564
Total Liabilities8,6198,7408,8999,45711,31912,3108,7639,83010,92911,33812,58415,272
Fixed Assets4,9115,1045,1075,4015,6486,3404,6094,8715,1835,0915,1766,966
CWIP5976116846719017688971,0901,5622,1033,6304,040
Investments408510312411569241239256424461
Other Assets3,0712,9393,0063,2624,6545,1333,0173,6313,9284,1013,7354,205
Total Assets8,6198,7408,8999,45711,31912,3108,7639,83010,92911,33812,58415,272
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7831,0991,2681,3031,1221,5431,7848386619711,0721,227
Cash from Investing Activity-362-309-465-614-1,018-267-727-323-474-596512-1,143
Cash from Financing Activity-503-843-686-901657-1,050-1,709-33-157-432-1,45395
Net Cash Flow-82-52117-212761225-65248230-58132179
Free Cash Flow4347608068194739751,270241-13583-38-120
CFO/OP141%91%104%103%84%116%155%90%111%131%112%114%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days526063555179495556504547
Inventory Days169207223177147463268308268220178170
Days Payable99106137145106273124139160146158170
Cash Conversion Cycle12216214987922681942241651246547
Working Capital Days12450454562745657561613
ROCE %6%13%15%15%16%15%12%10%3%7%10%9%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters50.67%50.67%50.67%50.67%50.67%50.67%50.67%47.67%47.67%47.67%47.67%47.67%
FIIs23.20%20.29%19.06%19.50%17.94%16.96%17.23%17.40%16.56%15.96%15.90%15.87%
DIIs1.64%2.89%3.77%4.06%5.66%6.99%7.05%9.52%10.53%11.23%11.63%12.40%
Public23.89%25.56%25.91%25.18%25.17%24.82%24.48%24.83%24.60%24.57%24.25%23.50%
Others0.59%0.58%0.58%0.58%0.56%0.56%0.56%0.56%0.63%0.57%0.56%0.55%
No. of Shareholders89,37686,58892,26481,99289,4561,02,44296,52699,67393,33690,13386,34782,703

Fundamentals

Market Cap₹ 16,698 Cr.
Current Price₹ 1,048
Stock P/E43.0
Book Value₹ 445
ROCE8.99 %
ROE6.53 %
Dividend Yield0.48 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)16%
Compounded Profit Growth (TTM)-20%
Consolidated figures.
Valuation
Market capRs 15,917 Cr
Enterprise valueRs 18,264 Cr
P/E (TTM)45.21x
Price to book2.24x
Price to sales1.85x
EV / EBITDA14.82x
EV / EBIT23.93x
EV / sales2.12x
Price to cash flow12.97x
Earnings yield2.21%
Dividend yield0.50%
P/E, 3-year average55.79x
P/B, 3-year average1.93x
P/E, 5-year average45.58x
P/B, 5-year average1.55x
Profitability
Operating margin (excl. other income)15.21%
Operating margin (incl. other income)15.29%
EBITDA margin14.32%
Pre-tax margin6.34%
Net profit margin4.09%
Net margin, latest quarter2.53%
ROE5.97%
ROCE8.39%
ROA2.86%
ROE, 3-year average7.25%
ROCE, 3-year average8.92%
ROA, 3-year average3.52%
ROE, 5-year average5.77%
ROCE, 5-year average7.77%
ROA, 5-year average2.89%
ROIC (approx.)5.23%
Tax rate35.27%
Other income / net worth0.10%
Growth
Sales growth (latest year)14.45%
Profit growth (latest year)-52.53%
Sales CAGR, 3 years9.64%
Sales CAGR, 5 years6.31%
Profit CAGR, 5 years-13.77%
Sales growth QoQ-2.65%
Profit growth QoQ-52.68%
Sales growth YoY (latest quarter)17.29%
Profit growth YoY (latest quarter)-45.09%
Per share
EPS (TTM)Rs 22.11
EPS (latest year)Rs 25.02
EPS (latest quarter)Rs 3.55
EPS, 3-year averageRs 27.52
EPS, 5-year averageRs 20.94
Book value per shareRs 445.30
Sales per shareRs 540.45
Cash flow per shareRs 77.02
Free cash flow per shareRs -7.53
Dividend per share (latest year)Rs 4.96
Dividend per share, 3-year averageRs 4.96
Dividend per share, 5-year averageRs 4.97
Dividends
Dividend payout19.82%
Dividend payout, 3-year average43.90%
Dividend payout, 5-year average37.73%
Efficiency
Asset turnover0.54x
Fixed asset turnover1.19x
Inventory turnover2.79x
Inventory days131 days
Debtor days47 days
Debtors turnover7.74x
Creditor days170 days
Cash conversion cycle47 days
Working capital days13 days
Leverage
Total debtRs 3,615 Cr
Cash and bankRs 1,268 Cr
Net debtRs 2,347 Cr
Debt to equity0.51x
Net debt / EBITDA1.90x
Interest coverage3.52x
Current ratio (filing 2026-03-31)1.62x
Quick ratio (filing 2026-03-31)1.13x
Trade payables (filing 2026-03-31)Rs 1,234 Cr
Owners' fund to total sources46.44%
Debt to assets23.67%
Cash flow
Cash from Operating Activity (latest year)Rs 1,227 Cr
Cash from Investing Activity (latest year)Rs -1,143 Cr
Cash from Financing Activity (latest year)Rs 95 Cr
Net Cash Flow (latest year)Rs 179 Cr
Free cash flow (latest year)Rs -120 Cr
FCFE (approx.: FCF + change in debt)Rs 764 Cr
Cash from ops / profit, 5 years2.88x
Sales to cash flow6.75x
Statement figures
Net sales (TTM)Rs 8,608 Cr
Net sales (latest year)Rs 8,280 Cr
Sales (latest quarter)Rs 2,229 Cr
Operating profit excl. other income (latest year)Rs 1,260 Cr
Operating profit (latest quarter)Rs 248 Cr
Other income (TTM)Rs 15 Cr
EBITDA (TTM)Rs 1,233 Cr
PBDT (TTM)Rs 1,016 Cr
Profit before tax (TTM)Rs 546 Cr
Tax (latest year)Rs 217 Cr
Net profit (TTM)Rs 352 Cr
Net profit (latest year)Rs 398 Cr
Net profit (latest quarter)Rs 56 Cr
Depreciation (TTM)Rs 470 Cr
Depreciation (latest quarter)Rs 127 Cr
Interest (TTM)Rs 217 Cr
Cost of goods sold (latest year)Rs 3,432 Cr
Total expenditure (latest year)Rs 7,020 Cr
Total income (latest year)Rs 8,286 Cr
Share capitalRs 16 Cr
ReservesRs 7,077 Cr
Shareholders' fundsRs 7,093 Cr
Total assetsRs 15,272 Cr
Net blockRs 6,966 Cr
Capital work in progressRs 4,040 Cr
InvestmentsRs 61 Cr
ReceivablesRs 1,070 Cr
InventoryRs 1,232 Cr
Other liabilitiesRs 4,564 Cr
Shares outstanding (crore)15.93
Ownership
Promoter holding47.67% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 45.2 is at the 90th percentile of its own 8.4-year range (median 16.4, low 6.9, high 255.0).
P/B 2.24 is at the 53th percentile (median 2.19).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodJUBLPHARMANifty 50Difference
1 week-6.1%-2.8% -3.3 pts
1 month+10.1%-6.8% +16.9 pts
3 months+3.1%-7.6% +10.7 pts
6 months+22.4%+0.4% +22.0 pts
1 year-6.7%-9.9% +3.2 pts
2 years-18.1%-13.6% -4.5 pts
3 years+129.6%+14.2% +115.5 pts
5 years+59.0%+27.9% +31.1 pts
54 mutual fund schemes hold about ₹1,275 Cr. Over three months 5 bought more and 48 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan Small Cap Fund1.14%390 -14%
Quant Small Cap Fund0.73%260 -19%
Kotak Multi Cap Fund0.54%158 -19%
Bandhan Focused Fund5.09%106 -7%
Aditya Birla SL Small Cap Fund0.71%44 -19%
HDFC Manufacturing Fund0.41%43 -15%
Abakkus Flexi Cap Fund0.66%42 +100%
Kotak Special Opportunities Fund2.41%41 -43%
Abakkus Small Cap Fund1.42%40 -2%
HDFC Pharma and Healthcare Fund0.85%28 -31%
Kotak Consumption Fund1.43%25 -13%
Bandhan Innovation Fund0.79%21 -18%
Nippon India Nifty Smallcap 250 Index Fund0.32%11 -15%
Aditya Birla SL Bal Bhavishya Yojna0.73%9 -16%
UTI Healthcare Fund0.55%8 -20%
Kotak Healthcare Fund1.15%8 -42%
SBI Nifty Smallcap 250 Index Fund0.32%6 -15%
Aditya Birla SL Pharma & Healthcare Fund0.51%5 -19%
Bandhan Healthcare Fund1.46%5 +100%
Motilal Oswal Nifty Smallcap 250 Index Fund0.32%4 -15%
Tata India Pharma & Healthcare Fund0.25%4 -73%
Bajaj Finserv Healthcare Fund0.76%3 -23%
ICICI Pru Nifty Smallcap 250 Index Fund0.32%3 -15%
HDFC NIFTY Smallcap 250 Index Fund0.32%2 -15%
Bandhan Contra Fund0.10%2 +100%

Red flags

F-score 4 of 8
explainDebt up, profit down Borrowings up 32% while net profit fell in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹2,229 Cr +17.3% vs Jun 2025. Net profit ₹56 Cr -45.1%.
Against our estimate for Jun 2026: sales -0.3%, profit -52.6% in line. Our estimate for Sep 2026: sales Rs 2,320 Cr, profit Rs 91 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-24Dividend - Rs 5 Per Share
2025-07-25Dividend - Rs 5 Per Share
2024-08-02Dividend - Rs 5 Per Share
2023-08-10Dividend - Rs 5 Per Share
2022-08-11Dividend - Rs 5 Per Share
2021-08-05 Dividend - Rs 5 Per Share
2021-02-04 Demerger
2020-03-09 Interim Dividend - Rs 5 Per Share
2019-09-12 Annual General Meeting/Dividend - Rs 4.50 Per Share
2018-09-12 Annual General Meeting/Dividend Rs 3 Per Share
2017-08-16 Annual General Meeting/ Dividend - Rs 3/- Per Share
2016-08-18 Annual General Meeting/ Dividend - Rs 3/- Per Share
2015-08-20 Annual General Meeting/ Dividend - Rs 3/- Per Share
2014-08-21Annual General Meeting / Dividend - Rs 3/- Per Share
2013-08-14Annual General Meeting And Dividend Rs.3/- Per Share
2012-08-14Annual General Meeting/ Dividend Rs 3 Per Share
2011-08-10Annual General Meeting And Dividend Rs.2/- Per Share
2010-11-25Scheme Of Demerger
2010-09-17Annual General Meeting And Dividend Rs.2/- Per Share
2009-06-29Dividend-Rs.1.50 Pr Share
2008-09-17Agm/Div-Rs.1.50 Per Share
2007-09-17Agm/Div-Rs.1.25/- Per Sh
2006-09-08Agm/Div-Rs.1.25/- Per Sh
DateTypeWhat it says
2026-09-28General UpdatesGeneral Updates
2026-09-11General UpdatesGeneral Updates
2026-09-01General UpdatesGeneral Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST
2026-08-28General UpdatesGeneral Updates
2026-08-26Shareholder meetingProceedings of Annual General Meeting held on August 26, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with...
2026-08-23General UpdatesGeneral Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A
2026-08-17Shareholder meetingVoting results.
2026-08-10Press ReleaseA press release dated August 10, 2026, titled "The Company has informed the Exchange regarding press release dated August 10, 2026".
2026-08-10Board meeting outcomeJubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-05Concall / analyst meetSchedule of meet
2026-08-02General UpdatesGeneral Updates - Newspaper advertisements titled Notice of 48th Annual General Meeting, E-voting, Record Date and Final Dividend Information
2026-08-01General UpdatesGeneral Updates - Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2025-26, if approved by the members at th...
2026-08-01General UpdatesGeneral Updates-Intimation regarding letter(s) dispatched to the shareholders whose email IDs are not registered, for AGM Notice, TDS Communication an...
2026-08-01Shareholder meetingNotice of Annual General Meeting to be held on August 26, 2026
2026-07-30General Updates- Submission of Copies of Newspaper Advertisement relating to Notice to Shareholders - Transfer of equity shares/dividend to IEPF
2026-07-29General Updates- Communication sent to Shareholders relating to notice of transfer Shares/Dividend to IEPF
2026-07-29General Updates- Submission of Copies of Newspaper Publications - Annual General Meeting of Jubilant Pharmova Limited scheduled to be held on Wednesday, August 26, 2...
2026-07-19General UpdatesGeneral Updates - Newspaper Advertisements - Dispatch of Postal Ballot
2026-07-18Shareholder meetingNotice of Postal Ballot
2026-07-16General UpdatesGeneral Updates
2026-07-16General UpdatesGeneral Updates
2026-06-30General UpdatesGeneral Updates
2026-06-26General UpdatesGeneral Updates
2026-06-24General UpdatesGeneral Updates
2026-06-19General UpdatesGeneral Updates
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd (JUBLPHARMA) has a market capitalisation of Rs 16,698 Cr. at the 2026-10-01 close.

What is the P/E ratio of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd trades at a P/E of 43.0 on trailing twelve-month profit, at the 2026-10-01 close.

What were Jubilant Pharmova Ltd's latest quarterly results?

In the Jun 2026 quarter, Jubilant Pharmova Ltd sales was Rs 2,229 Cr (+17.3% vs Jun 2025) and net profit was Rs 56 Cr.

What is the 52-week high and low of Jubilant Pharmova Ltd?

The 52-week high is Rs 1,184.80 and the 52-week low is Rs 786.05.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03